How soon will Wegovy work — and what does 'working' actually mean?

The first decision: are you measuring the right thing?

A question our prescribers hear most weeks is some version of: 'I've been on Wegovy for three weeks and I've only lost two pounds, is it working?' The honest answer is that two pounds of weight loss at three weeks, while the dose is still at its lowest, is actually consistent with how semaglutide works. The early phase isn't designed to produce dramatic numbers. It's designed to let your body adjust to the medicine before the dose rises.

What's worth measuring in the first month isn't scale weight alone. Many people notice they're leaving food on the plate, losing interest in snacking, or feeling full after noticeably smaller portions. These appetite signals are the mechanism in motion, semaglutide acts on GLP-1 receptors involved in hunger regulation and slows gastric emptying, which extends the feeling of fullness after eating. If those changes are present, the medicine is doing what it's supposed to do at this stage.

The practical decision here is whether to set your expectations against the full 68-week trial timeline rather than the first month. The STEP 1 trial, published in the New England Journal of Medicine, found average weight loss of around 15% over 68 weeks, a result built up gradually across the full titration schedule, not delivered in the opening weeks.

For a broader look at how the medicine is structured and what it's licensed for, the Wegovy overview page covers the essentials clearly, and if you want to look up the full product information, the Wegovy Vidal reference is a useful place to check the licensed details.

How the dose schedule shapes your results

Wegovy follows a stepped titration: doses increase roughly every four weeks, moving from 0.25 mg through 0.5 mg, 1.0 mg, 1.7 mg, and up to the 2.4 mg maintenance dose, or, where clinically appropriate, the 7.2 mg dose approved by the MHRA in early 2026. Each step up typically brings a fresh wave of appetite suppression, and it's common to notice a more pronounced effect after each increase.

This matters for your timeline because most of the weight loss accelerates once you're on or approaching the maintenance dose. Results at 0.25 mg or 0.5 mg are modest by design. The prescriber sets the schedule for tolerability (reducing the nausea and gastrointestinal discomfort that can come with GLP-1 medicines) not for speed. Trying to rush through doses would increase the risk of side effects without meaningfully improving the outcome.

The NHS semaglutide medicines page describes what to expect at each stage and lists common side effects, which tend to peak after dose increases and settle within a couple of weeks. If you're thinking about how your own starting point affects the likely trajectory, the question of whether Wegovy is right for you individually is worth exploring separately.

What the clinical evidence actually shows about timing

The STEP 1 trial data offers the most reliable reference point for expectations. At 16 weeks, participants on semaglutide 2.4 mg had lost an average of around 6–7% of their body weight. By 68 weeks, that figure had reached approximately 15%. The curve is not linear: weight loss tends to be faster in the middle phase of treatment, after titration is complete, and then gradually plateaus as the body reaches a new equilibrium.

A smaller group of participants in the trial experienced less than 5% loss at 16 weeks, a threshold that clinical guidelines use as an early indicator of response. This is something a prescriber reviews at each clinical check-in; NICE's recommendations on semaglutide note that continuing treatment should be assessed if early response is limited. That's one of the reasons the structure of ongoing clinical review matters for this medicine.

If you're researching cost alongside effectiveness, there's a useful summary of what Wegovy costs privately in the UK and what any quoted price should include. Separately, for people weighing up how the injection and tablet forms compare, the semaglutide page gives a plain-English breakdown of both licensed options.

When to flag slow progress to your clinical team

Most people notice meaningful appetite changes within the first four to eight weeks; weight on the scales follows in the weeks after that. If by week twelve you've had no change in appetite, no shift in eating habits, and no movement on weight despite being consistent with the medicine and making genuine dietary changes, that's worth raising with your prescriber. It doesn't necessarily mean the treatment isn't suitable, but it does warrant a clinical review.

Side effects (nausea, indigestion, loose stools) are common, particularly after dose increases, and are not a sign that something is wrong. They do, however, sometimes cause people to eat even less than intended, which can temporarily accelerate early weight loss before settling. It's worth distinguishing between that and the more sustained appetite regulation the medicine produces at therapeutic doses.

The detailed look at how soon Wegovy takes effect covers the early-weeks experience in more granular terms. And if you'd like to understand the broader range of weight-loss treatment options before deciding, the weight management overview is a reasonable starting point.

Wegovy is a prescription-only medicine. If you'd like to explore whether it's clinically appropriate for you, check your eligibility with our prescribers through a free consultation, reviewed the same day by a GPhC-registered prescriber, not an automated process.